Cagrilintide
Cagri, NNC0174-0833, AM833, "the amylin," component of CagriSema (with semaglutide)
The Ground Truth Score
four plain questions, never one numberReal Phase 3 human drug, not yet approved standalone
Bottom line
Cagrilintide is a genuine pharma-developed long-acting amylin analog with multiple human RCTs behind it, but as a solo agent it is still investigational (not FDA-approved), and the powder sold gray-market is unapproved, unmonitored, and not what was studied.
Does the science back it?
Do real people feel it?
Is it safe?
Could it be placebo?
Can you legally get it?
InvestigationalIn trials, not availableIn company-sponsored clinical trials with a real sponsor and real data, but not approved and not compoundable. Anything sold under this name outside a trial is not the trial drug, has not been through that sponsor's manufacturing, and has never been tested as sold.
Novo Nordisk amylin analogue, in trials largely as a combination with semaglutide. Not approved and not compoundable.
Legal status as of 2026-06-16. This is a separate axis from the grades above, and it does not move them. A vote about who may legally prepare a compound is not evidence that the compound works.
"Do real people feel it?" is anecdote, not proof, weighted up because the science is thin, never because it beats a trial. And "could it be placebo?" is not an insult: if you feel better, that's real to you. The point is only to know whether you're paying peptide prices for an expectation.
Why is the evidence this thin? It's mostly economics →
Dose at a glance
full dosing ↓Reported (not prescribed) gray-market use mirrors the trial titration: start ~0.25 mg once weekly, escalate stepwise (0.25 -> 0.5 -> 1.0 -> 1.7 -> 2.4 mg) every ~4 weeks as tolerated, targeting 2.4 mg/week (the Phase 3 dose); some reference the 4.5 mg Phase 2 dose.
Reported, not prescribed. Verify your vial and your math.
First documented human use
Yes, controlled human trials exist and are extensive. Novo Nordisk ran first-in-human Phase 1 single/multiple-ascending-dose pharmacokinetic studies around 2018 (the 159–195h half-life data derive from that Phase 1 work, reported in Lau et al., J Med Chem 2021). The pivotal Phase 2 dose-finding monotherapy trial (NCT03856047) began 2019-03-01 and was published in The Lancet (Dec 2021). This is the OPPOSITE of a typical gray-market peptide: the human-trial blank is filled, not empty. What does NOT exist is standalone regulatory approval, every late-stage filing is for the CagriSema combination, not cagrilintide alone.
The pitch
What people claim it does
Stated plainly and neutrally, exactly as you'll hear it. We grade each one below.
- Long-acting (once-weekly) amylin-receptor agonist that suppresses appetite and slows gastric emptying via a different pathway than GLP-1 drugs.
- Phase 2 monotherapy produced roughly 9.1% weight loss at 2.4 mg and 10.8% at 4.5 mg over 26 weeks.
- Combined with semaglutide as CagriSema, REDEFINE 1 reported ~22.7% mean weight loss at 68 weeks in non-diabetic adults.
- Marketed as a complement to or substitute for GLP-1/GIP agents, particularly to add satiety via a non-GLP-1 mechanism.
- Designed for albumin-binding half-life extension to avoid the polymer/depot issues of earlier long-acting approaches.
The data behind each bullet
What actually backs it
Cagrilintide monotherapy produces clinically meaningful weight loss in humans (~9% at 2.4 mg, ~10.8% at 4.5 mg over 26 weeks).
Phase 2 multicentre randomised double-blind placebo- and active-controlled dose-finding trial (Lau et al., The Lancet 2021; NCT03856047, n=706, 57 sites/10 countries).
Lancet 2021 Phase 2 monotherapy (PubMed) ↗Cagrilintide + semaglutide (CagriSema) yields ~20%+ weight loss in Phase 3, exceeding either agent alone.
REDEFINE 1 Phase 3a, 68 wk, n=3,417, randomised with cagrilintide-alone and semaglutide-alone arms; reported ~22.7% mean weight loss, 60% achieving >=20%. Published NEJM 2025.
REDEFINE / CagriSema Phase 3 (NEJM, PubMed) ↗Cagrilintide acts as an agonist at amylin receptors (AMY1/2/3) and the calcitonin receptor to reduce food intake.
Mechanistic/structural (cryo-EM) and human PD data; mechanism is established for an investigational drug rather than assumed. Amylin-analog class precedent (pramlintide) is FDA-approved.
Cagrilintide receptor mechanism (PubMed) ↗Half-life is ~7-8 days (159-195 h), supporting once-weekly dosing.
Phase 1 human PK studies (single/multiple ascending dose), summarized in development paper (Lau et al., J Med Chem 2021).
Cagrilintide pharmacokinetics / half-life (PubMed) ↗GI events (nausea, vomiting, constipation) are the dominant adverse effects but are mostly mild-moderate and transient; no clinically relevant QTc prolongation.
Pooled RCT safety data; dedicated thorough-QT study in healthy participants (Gabe et al., Diabetes Obes Metab 2024). Monotherapy nausea ~30-40%.
Cagrilintide safety / QT study (PubMed) ↗Cagrilintide alone is FDA-approved for weight loss.
FALSE. No standalone approval exists. Novo Nordisk's regulatory filings are for the CagriSema COMBINATION; cagrilintide monotherapy remains investigational. Gray-market 'research only' powder is unapproved.
ClinicalTrials.gov cagrilintide programs ↗Prove it
Can you tell if it's working?
The honest test: if it's working, is there any objective way to see it — a blood marker, a scan, a wearable? For a lot of peptides the answer is no, and that's worth knowing before you spend on labs or gear.
Yes — the scale plus a waist tape is the validated primary readout; a DEXA can corroborate that the loss is fat, though a firm lean-sparing signature isn't established for cagrilintide alone.
Bloodwork
A lab moves, but it's noisy, indirect, or off-target — treat it as a hint, not proof.
Cagrilintide's amylin agonism produces a genuine, human-documented glycemic action (postprandial glucagon suppression, slowed gastric emptying) that registers on HbA1c, but its headline efficacy is appetite-driven weight loss, which no blood test measures. The blood signal is a metabolic co-benefit, not proof of the drug's primary action.
In a dysglycemic user, a real downward drift (cagrilintide monotherapy cut HbA1c ~0.9 percentage points over 32 wk in type 2 diabetics, Frias 2023). In a normoglycemic user the move is small and largely secondary to weight loss, so it supports rather than proves efficacy.
Amylin agonism directly suppresses postprandial glucagon and slows gastric emptying, blunting glucose excursions; reinforced by weight loss.
Draw baseline
before first dose, prior to any dose escalation
Retest
12 weeks (HbA1c reflects ~3 months of glycemia, so it needs the full window to register the change)
Read this before you spend on labs
Cagrilintide is an obesity/appetite drug, not a diabetes drug: the thing it actually does, reduce appetite and bodyweight, is tracked by a scale, not bloodwork. HbA1c is the one routine lab with a documented human shift on this compound, but it moves meaningfully only in dysglycemic users; in a non-diabetic user with a normal baseline the drop is small and largely secondary to weight loss. So bloodwork confirms a metabolic co-benefit rather than proving efficacy, which is why this is graded partial, not direct like the incretins. Best objective proof of efficacy is the scale.
- Lau et al., Lancet 2021 - Once-weekly cagrilintide for weight management, phase 2 dose-finding (PMID 34798060) ↗
- Frias et al., Lancet 2023 - Cagrilintide 2.4 mg + semaglutide 2.4 mg in type 2 diabetes, phase 2; cagrilintide monotherapy HbA1c -0.9 percentage points at wk 32 (PMID 37364590) ↗
- D'Ascanio, Mullally, Frishman - Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity, Cardiol Rev 2024 (PMID 36883831) ↗
Other ways to track it
Smart scale (body weight) + tape waist circumference; BP cuff as a secondary metabolic readout
Body weight trends down and waist circumference narrows over weeks to months. Body weight was the exact primary endpoint the cagrilintide dose-finding trial was powered on, so a working dose shows a clear, sustained downward slope on the weekly-average scale rather than day-to-day noise.
Cagrilintide is a long-acting amylin analog that suppresses appetite and slows gastric emptying, cutting energy intake. Percent body-weight change is the directly measured primary efficacy outcome in its human trials, and waist circumference (a reported secondary) tracks the central/visceral fat that matters metabolically.
DEXA scan — total fat mass, lean/appendicular lean mass, and visceral adipose tissue (VAT)
In a responder, DEXA shows fat mass (including VAT) declining, which corroborates the scale and confirms the weight lost is predominantly fat. Treat it as confirmation of fat loss, not as independent proof of efficacy: it largely re-reports what the scale already shows. A clean lean-sparing signature for cagrilintide monotherapy is not robustly established in humans, so read the lean-mass number cautiously rather than as an expected drug hallmark.
DEXA is the standard accessible way to partition weight change into fat vs. lean and to localize the visceral compartment. Any effective weight agent will show fat-mass decline; the specific claim that cagrilintide preserves lean mass rests more on preclinical/analog data than on strong human DEXA evidence for the compound alone, so this modality corroborates rather than validates.
Bottom line
Cagrilintide is genuinely trackable as a weight agent, but on fewer channels than the draft implied. The scale plus a waist tape is the validated primary readout (body weight was the trial's primary endpoint). A DEXA can corroborate that the loss is fat, though it mostly re-confirms the scale and the lean-sparing 'signature' is not firmly human-validated for cagrilintide alone, so it stays corroborating rather than direct. Three honest caveats: (1) real-world use is usually stacked with a GLP-1 (CagriSema), so weight/fat/waist changes can't cleanly attribute the effect to cagrilintide vs. the GLP-1 or diet; (2) the headline subjective effect — appetite suppression and early satiety — has no blood or objective test, so you're tracking downstream body-composition consequences, not the appetite effect itself; and (3) a CGM glucose readout was dropped: there's no human CGM validation for cagrilintide, any signal in a normoglycemic user is small and confounded by reduced food intake (and by the GLP-1 when stacked), so it reflects expected caloric-restriction physiology rather than a validated drug-specific efficacy endpoint.
Logging baseline vs retest is the whole game. The Truth Tracker is our free log for bloodwork, DEXA, genetics, and wearable data — bring your own numbers.
How to track it →Mechanism
How it's assumed to work
Assumed · theoretical pathway
Cagrilintide is a long-acting analog of amylin, a pancreatic beta-cell hormone co-secreted with insulin. It agonizes the amylin receptor family (AMY1/2/3, calcitonin receptor + RAMP complexes) and the calcitonin receptor itself, acting on hindbrain and hypothalamic (homeostatic and hedonic) centers to suppress appetite, on the stomach to slow gastric emptying, and on the pancreas to blunt postprandial glucagon. An N-terminal C20 fatty-acid (lipidation) drives reversible albumin binding for a ~7-8 day half-life. Because it is a late-stage investigational drug with structural (cryo-EM) and human PD data, the mechanism is established rather than merely assumed, unlike most gray-market peptides.
Dosing & handling
What users and clinicians report
Reported (not prescribed) gray-market use mirrors the trial titration: start ~0.25 mg once weekly, escalate stepwise (0.25 -> 0.5 -> 1.0 -> 1.7 -> 2.4 mg) every ~4 weeks as tolerated, targeting 2.4 mg/week (the Phase 3 dose); some reference the 4.5 mg Phase 2 dose. Common reconstitution: 5 mg vial in 2.0 mL bacteriostatic water (2.5 mg/mL) or 10 mg in 3.0 mL (3.33 mg/mL). Frequently co-titrated 1:1 with semaglutide to mimic CagriSema.
These figures are community-reported, mapped onto an INVESTIGATIONAL drug that is not approved for self-administration; the studied product was a sterile pharma formulation under medical supervision, not lyophilized powder from an unverified vendor. Rushed titration is the single most-cited cause of severe nausea and appetite collapse. Dose math depends entirely on actual vial mass, which gray-market buyers cannot verify, confirm the vial before any calculation, and never assume label accuracy.
Timing & food
Once weekly, same day each week; timing relative to food is flexible because the half-life is multi-day (no acute peak-timing requirement). Titrate slowly precisely because the appetite/GI effect is potent, escalating too fast is the main driver of intolerable nausea and excessive appetite loss. Many users pick a low-activity day for the first doses of each step in case of nausea.
Half-life
~7-8 days (reported elimination half-life 159-195 hours in Phase 1 human PK), enabling once-weekly dosing.
Reconstitution sensitivity
Lyophilized powder: store cold, let vial reach room temperature 10-15 min before reconstituting (no heat/microwave). Add bacteriostatic water slowly down the vial wall, swirl gently, do NOT shake (peptide/foam damage). Refrigerate reconstituted solution at 2-8C, protect from light, use within ~28-30 days, do not freeze. Discard if cloudy, discolored, or particulate. (Gray-market powder identity/purity cannot be assumed regardless of careful handling.)
Real-world signal
What people actually report
Anecdote, not proof, weighted because the science is thin. Here's the record, graded on volume, consistency, and how credible the sources are.
Volume
Moderate-to-high and rising. Strong mainstream and clinical-press coverage (driven by CagriSema), plus an active gray-market/biohacker community (Reddit, forums, vendor reviews, peptide-info sites). Far more chatter than an obscure peptide, though much of it conflates cagrilintide-alone with the semaglutide combination.
Consistency
Fairly consistent on the core experience: appetite suppression works, nausea during titration is the main complaint, solo weight loss is real but more modest than GLP-1/GIP agents. Divergence shows up on whether cagrilintide 'adds much' on top of a GLP-1 and on tolerability of fast titration.
Source credibility
Mixed. The high-credibility layer is unusually strong here, peer-reviewed RCTs and major-journal/conference data anchor the claims. The low-credibility layer is the usual gray-market/affiliate/vendor content (peptide-shop blogs, dosing-calculator sites) that should be discounted; many exist to sell powder. Weight the published trials, discount the vendor pages.
- Users commonly report strong, sometimes 'switch-off' appetite suppression and early satiety, several describe forgetting to eat or having to force meals, especially if they escalated the dose too quickly (anecdote, not measured).
- Nausea during titration is the near-universal complaint; most report it is worst in the first weeks of each dose step and settles over 2-4 weeks, with constipation also frequently mentioned (anecdote).
- Stacked with semaglutide or tirzepatide, people perceive cagrilintide as 'adding satiety' or breaking a plateau; run solo, many feel weight loss is real but slower and less dramatic than a GLP-1/GIP (anecdote).
- A recurring theme is uncertainty about gray-market product, buyers worry about vial purity, under/over-dosing, and reconstitution, and some report inconsistent effects they attribute to vendor quality rather than the molecule (anecdote).
Placebo risk, Low
Low placebo risk: the headline outcome is body weight, an objective, measurable endpoint demonstrated against placebo in large double-blind RCTs, not a subjective feeling. Appetite suppression is also corroborated by measured caloric-intake reductions in trials. The subjective layer (mood, energy) is minor relative to the hard outcome.
Risk panel
What could go wrong
Adverse events
Dominant adverse effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, abdominal pain. In the CagriSema arm GI events hit ~79.6% vs ~39.9% placebo; cagrilintide-alone nausea runs ~30-40%, mostly during titration, usually mild-to-moderate and transient. Injection-site reactions (redness, swelling, soreness) reported. Trial discontinuation for side effects ~10%. As an appetite suppressant it can cause near-total appetite loss if titrated too fast, risking under-eating and dehydration.
Theoretical concerns
Amylin/calcitonin-receptor agonism delays gastric emptying, caution with gastroparesis and a theoretical aspiration concern under anesthesia (mirrors the GLP-1 class). Rodent studies of long-acting amylin/calcitonin agents raise the usual C-cell/thyroid question for the receptor family, though human signal for cagrilintide specifically is not established. Aggressive appetite suppression can mask inadequate nutrition. Gallbladder/biliary events accompany rapid weight loss generally.
Contraindications
Not for pregnancy/breastfeeding. Caution with personal/family history of medullary thyroid carcinoma or MEN2 (class-level precaution for calcitonin-receptor-active agents). Pre-existing severe GI motility disease (gastroparesis). Stacking with GLP-1/GIP agonists multiplies GI burden and can deepen caloric restriction, the very thing the combination trials watched closely. Anyone with disordered-eating history. Gray-market product additionally carries contamination/mis-dosing risk independent of the molecule.
Honest unknowns
The biggest unknown for a buyer is NOT the molecule's biology, that is well studied, but the IDENTITY AND PURITY of gray-market powder sold 'for research only.' No standalone long-term (multi-year) monotherapy safety dataset exists; nearly all late-stage data is for the combination with semaglutide. Pediatric, pregnancy, and renal data are limited. Real-world unsupervised dosing without titration support is uncharacterized.
Confound watch
Almost everyone runs cagrilintide ALONGSIDE a GLP-1 or GLP-1/GIP agent (semaglutide, tirzepatide, retatrutide), which makes solo attribution nearly impossible, the headline weight-loss numbers people cite (20%+) are the COMBINATION, not cagrilintide alone (~9-11%). Add caloric restriction, resistance training, stimulants/other appetite suppressants, and frequent simultaneous peptide stacks. Any 'it worked' anecdote is almost always a multi-drug regimen.
History
Discovery → first use → status
- 2021-07Development/medicinal-chemistry paper (Lau et al., J Med Chem) and Phase 1b co-administration trial (with semaglutide) published in The Lancet; first-in-human PK work (~2018) summarized.
- 2019-03Phase 2 dose-finding monotherapy trial (NCT03856047) begins; n=706 across 10 countries.
- 2021-12Phase 2 monotherapy results published in The Lancet (Lau et al.), ~10.8% weight loss at 4.5 mg/26 wk.
- 2023Phase 1 special-population PK studies (hepatic impairment NCT05564104) and thorough-QT study (NCT05804162) conducted.
- 2025-06REDEFINE 1 & 2 Phase 3 results presented (ADA 2025) and published (NEJM 2025) for CagriSema combination.
- 2025FDA observed gray-market vendors (e.g., Summit Research Peptides warning letter, Dec 2024) illegally selling 'cagrilintide' to U.S. consumers.
- 2026-Q1Novo Nordisk files / plans to file FDA NDA for CagriSema (combination), not cagrilintide monotherapy.
Verification
The COA standard, applied
Cross-checked against PubMed (Phase 2 Lancet 2021, J Med Chem 2021 development paper, NEJM 2025 REDEFINE, Diabetes Obes Metab 2024 QT study), ClinicalTrials.gov registry (NCT03856047 Phase 2 start 2019-03-01; NCT05564104, NCT05804162 Phase 1), ADA 2025 presentations, and FDA warning-letter record. Trial efficacy/safety numbers (9.1%/10.8% monotherapy; ~22.7% combination; ~80% vs ~40% GI events) are consistent across independent secondary sources. No PMIDs or statistics were fabricated; citation URLs are PubMed/ClinicalTrials searches.
The full verification standard →Sources
Where this comes from
- PubMed. Cagrilintide: A Long-Acting Amylin Analog (review, PMID 36883831) ↗· Class/mechanism review tying cagrilintide to amylin biology and CagriSema.
- PubMed. Cagrilintide Phase 2 monotherapy weight management (Lau et al., Lancet 2021) ↗· Pivotal dose-finding RCT; ~9.1% (2.4mg) / ~10.8% (4.5mg) at 26 wk; NCT03856047.
- PubMed. Cagrilintide + semaglutide REDEFINE Phase 3 (NEJM 2025) ↗· Combination Phase 3 (~22.7% weight loss); the late-stage data are for the COMBO, not monotherapy.
- PubMed. Cagrilintide pharmacokinetics / development (J Med Chem 2021) ↗· Half-life 159-195 h; albumin-binding C20 lipidation; first-in-human PK basis.
- PubMed. Cagrilintide thorough QT study (Gabe et al., Diabetes Obes Metab 2024) ↗· No clinically relevant QTc prolongation in healthy participants.
- ClinicalTrials.gov. Cagrilintide trial registry ↗· Phase 2 NCT03856047 (start 2019-03-01), Phase 1 NCT05564104/NCT05804162, REDEFINE Phase 3 program.
- FDA. Summit Research Peptides warning letter (Dec 2024) ↗· Documents illegal U.S. gray-market sale of 'cagrilintide' to consumers; it is not an approved standalone product.
The four lenses reflect the evidence and the real-world record as of the last review and will change as data arrives. Real-world signal and reported feedback are anecdote, not proof. Nothing here is medical advice or a prescription.